📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-11 17:15
711 analysed today
711
Today
133,600
All-time analysed
40,124
Positive
6,284
Negative
79,372
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
1 announcement match the current filters (relevance ≥ 5).
₹7.57 Cr Revenue in Q1 FY27, up 166% YoY; Net Profit rises to ₹0.22 Cr
Beryl Drugs reported a significant top-line expansion in Q1 FY27, with total revenue reaching ₹7.57 Cr, a 166% increase from ₹2.84 Cr in Q1 FY26. Net profit surged to ₹22.08 Lakhs compared to just ₹2.11 Lakhs in the same period last year, although it declined sequentially from ₹56.25 Lakhs in Q4 FY26. The sequential profit drop is attributed to a sharp spike in 'Other Expenses,' which rose to ₹1.86 Cr from ₹0.38 Cr in the previous quarter. Despite margin pressure, the company remains profitable with an EPS of ₹0.47 for the quarter.
Confidence: HIGH
What changedThe company has achieved a significant scale-up in quarterly revenue, moving from a quarterly average of ~₹4.8 Cr in FY26 to over ₹7.5 Cr in Q1 FY27.
Why it mattersFor a micro-cap company with a ₹12 Cr market capitalization, this level of revenue growth suggests a potential structural shift in business volume or the execution of a large new contract.
Revenue (Q1 FY27): ₹7.57 CrYoY Revenue Growth: 166%Q1 Revenue vs TTM Revenue: ~39.8%Net Profit (Q1 FY27): ₹0.22 CrOther Expenses: ₹1.86 Cr
📅 Short termThe strong YoY growth is likely to be viewed positively by the market, though the sequential decline in PAT due to higher expenses may lead to some volatility.
📈 Long termIf the company can maintain this higher revenue base while optimizing operating costs, it could lead to a significant re-rating of the stock given its small base.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant volatility in 'Other Expenses'
- Low promoter holding at 27.8%
- Micro-cap liquidity risk
Key Highlights
Total Revenue from operations grew 166% YoY to ₹7.57 Cr, representing nearly 40% of the entire FY26 revenue.
Net Profit increased more than 10x YoY to ₹22.08 Lakhs from ₹2.11 Lakhs.
Other Expenses surged to ₹1.86 Cr in Q1 FY27, compared to ₹0.38 Cr in Q4 FY26 and ₹1.73 Cr in Q1 FY26.
Cost of materials consumed rose to ₹4.34 Cr, up from ₹2.21 Cr in the corresponding quarter of the previous year.
Earnings Per Share (EPS) stood at ₹0.47 for the quarter, up from ₹0.04 YoY.
👀 What to Watch
Investors should monitor if this elevated revenue run-rate is sustainable over the coming quarters and watch for any management commentary regarding the spike in 'Other Expenses' which impacted sequential margins.
